Judith M. Ramage

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis

Nicholas FS Watson, Judith M. Ramage, Zahra Madjd et al. · International Journal of Cancer · 2005 · 246 citations

Costimulation via CD55 on Human CD4+ T Cells Mediated by CD97

Melania Capasso, Lindy G. Durrant, Martin Stacey et al. · The Journal of Immunology · 2006 · 116 citations

Inflammation, Complement System, Cell Therapy +15

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer

Amy Popple, Lindy G. Durrant, Ian Spendlove et al. · British Journal of Cancer · 2012 · 103 citations · Full text

<i>In vitro</i> responses of human CD45R0^brightRA⁻ and CD45R0⁻RA^bright T cell subsets and their relationship to memory and naive T cells

Joyce L. Young, Judith M. Ramage, J. S. Hill Gaston et al. · European Journal of Immunology · 1997 · 92 citations

Complement decay accelerating factor (DAF)/CD55 in cancer

Ian Spendlove, Judith M. Ramage, Richard Bradley et al. · Cancer Immunology Immunotherapy · 2006 · 65 citations · Full text

Medicine, Immunology, Cell Death +5